<p>/PRNewswire/ --2025 年 12 月 5 日，深圳微芯生物科技有限公司創始人兼董事長盧顯平博士被評選為 2025 年安永年度企業家獎™中國大陸獲獎者。</p>
<p>這一榮譽表彰了他在推動新質量生產力和推動製藥行業創新方面的傑出貢獻。</p>
<p>繼續閲讀</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null"/></p>
<p>盧顯平博士在頒獎典禮上發表講話。</p>
<p>本次獎項以&#34;二十年的堅定力量，邁向新時代&#34;為主題，慶祝那些肩負新時代責任併為國家繁榮和社會進步做出重大貢獻的企業家。</p>
<p>盧顯平博士是中國創新制藥領域傑出的科學家和企業家。他獲得了北京協和醫學院的分子生物學博士學位，在美國進行博士後研究，併成功創辦了兩家生物製藥公司。出於&#34;為普通人開發可負擔的創新藥物&#34;的使命，他選擇回國，於 2001 年成立了微芯生物。</p>
<p>在中國歷史上對仿製藥的關注背景下，盧博士致力於研究具有全新作用機制的首創藥物。通過建立基於化學基因組學和人工智能輔助設計的新藥發現與評估平台，他顯著提高了研發成功率並縮短了開發週期。在他的領導下，Chidamide 成為中國首個原創小分子抗腫瘤創新藥物，也是中國首個全球許可的藥品，填補了中國外周 T 細胞淋巴瘤治療的關鍵空白，併為乳腺癌、成人 T 細胞白血病、瀰漫大 B 細胞淋巴瘤等惡性腫瘤患者帶來了新的希望。經過 19 年的研發，Chiglitazar Sodium 作為全球首個 PPAR 全激動劑，標誌着 2 型糖尿病領域的歷史性突破。這兩種藥物均已納入中國國家醫保藥品目錄（NRDL），大幅減輕了患者的經濟負擔。目前的研發管線中，多個具有顯著首創潛力的藥物候選者預計將為阿爾茨海默病等慢性疾病提供新的治療選擇。</p>
<p>盧博士積極推動中國製藥生態系統的改善，包括創新藥物審評路徑的演變、NRDL 納入機制和資本市場改革。在他的指導下，微芯生物已捐贈超過 7 億人民幣的藥品，幫助超過 10,000 名患者減輕治療費用。致力於開發具有新靶點、結構和機制的首創療法，他被國際媒體譽為&#34;中國原創創新藥物的先驅&#34;。</p>
<p>來源：深圳微芯生物科技有限公司。</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMjI5Jk5ld3NJdGVtSWQ9Q041NDE5NyZUcmFuc21pc3Npb25fSWQ9MjAyNTEyMjkxOTQ1UFJfTkVXU19VU1BSX19fX19DTjU0MTk3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMjI5Jk5ld3NJdGVtSWQ9Q041NDE5NyZUcmFuc21pc3Npb25fSWQ9MjAyNTEyMjkxOTQ1UFJfTkVXU19VU1BSX19fX19DTjU0MTk3"/></p>

微芯生物

<p>深圳微芯生物創始人兼董事長盧顯平博士被評選為 2025 年安永年度企業家獎™中國大陸獲獎者。這一榮譽突顯了他在製藥行業創新方面的貢獻。盧博士擁有分子生物學博士學位，於 2001 年創立微芯生物，致力於開發可負擔的創新藥物。他的領導下，創造瞭如奇達莫德和奇格利他鈉等重要藥物，改善了多種癌症和糖尿病的治療選擇。他還為提升中國的製藥生態系統做出了貢獻，並向患者捐贈了超過 7 億人民幣的藥品</p>

<p>, /PRNewswire/ -- On December 5, 2025, Dr. Lu Xianping, Founder, Chairman of Shenzhen Chipscreen Biosciences Co., Ltd, has been named the Chinese mainland winner of the EY Entrepreneur Of The Year™ 2025 awards.</p>
<div class="lb-trans"><p>/PRNewswire/ --2025 年 12 月 5 日，深圳微芯生物科技有限公司創始人兼董事長盧顯平博士被評選為 2025 年安永年度企業家獎™中國大陸獲獎者。</p>
</div><p>This recognition honors his outstanding contributions to advancing new-quality productive forces and driving innovation within the pharmaceutical industry.</p>
<div class="lb-trans"><p>這一榮譽表彰了他在推動新質量生產力和推動製藥行業創新方面的傑出貢獻。</p>
</div><p>Continue Reading</p>
<div class="lb-trans"><p>繼續閲讀</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null" alt="" original-src="https://www.prnewswire.com/news-releases/null"/></p>
<p>Dr. Lu Xianping delivers his remarks at the award ceremony.</p>
<div class="lb-trans"><p>盧顯平博士在頒獎典禮上發表講話。</p>
</div><p>The award program, themed &#34;Two Decades of Unwavering Strength, Forging Ahead in the New Era,&#34; celebrates entrepreneurs who shoulder new-era responsibilities and contribute significantly to national prosperity and social progress.</p>
<div class="lb-trans"><p>本次獎項以&#34;二十年的堅定力量，邁向新時代&#34;為主題，慶祝那些肩負新時代責任併為國家繁榮和社會進步做出重大貢獻的企業家。</p>
</div><p>Dr. Lu Xianping stands as a distinguished scientist and entrepreneur in China's innovative pharmaceutical sector. He earned a Ph.D. in Molecular Biology from Peking Union Medical College, pursued postdoctoral research in the U.S., and successfully founded two biopharmaceutical companies. Driven by the mission to &#34;develop affordable innovative drugs for ordinary people,&#34; he chose to return to China and established Chipscreen Biosciences in 2001.</p>
<div class="lb-trans"><p>盧顯平博士是中國創新制藥領域傑出的科學家和企業家。他獲得了北京協和醫學院的分子生物學博士學位，在美國進行博士後研究，併成功創辦了兩家生物製藥公司。出於&#34;為普通人開發可負擔的創新藥物&#34;的使命，他選擇回國，於 2001 年成立了微芯生物。</p>
</div><p>Against the backdrop of China's historical focus on generic drugs, Dr. Lu dedicated himself to researching first-in-class drugs with entirely novel mechanisms of action. By building a new drug discovery and evaluation platform based on chemical genomics and AI-assisted design, he significantly improved R&amp;D success rates and shortened development cycles. Under his leadership, Chidamide became China's first original small-molecule anti-tumor innovative drug and the country's first pharmaceutical product to be globally licensed out. It filled a critical gap in treating peripheral T-cell lymphoma in China and has extended new hope to patients with breast cancer, adult T-cell leukemia, diffuse large B-cell lymphoma and other malignancies. Chiglitazar Sodium, developed over 19 years for Type 2 diabetes, marked a historic breakthrough as the world's first PPAR pan-agonist. Both drugs have been included in China's National Reimbursement Drug List (NRDL), substantially reducing patients' financial burdens. In the current pipeline, multiple drug candidates with significant first-in-class potential are expected to deliver novel therapeutic options for chronic diseases such as Alzheimer's disease.</p>
<div class="lb-trans"><p>在中國歷史上對仿製藥的關注背景下，盧博士致力於研究具有全新作用機制的首創藥物。通過建立基於化學基因組學和人工智能輔助設計的新藥發現與評估平台，他顯著提高了研發成功率並縮短了開發週期。在他的領導下，Chidamide 成為中國首個原創小分子抗腫瘤創新藥物，也是中國首個全球許可的藥品，填補了中國外周 T 細胞淋巴瘤治療的關鍵空白，併為乳腺癌、成人 T 細胞白血病、瀰漫大 B 細胞淋巴瘤等惡性腫瘤患者帶來了新的希望。經過 19 年的研發，Chiglitazar Sodium 作為全球首個 PPAR 全激動劑，標誌着 2 型糖尿病領域的歷史性突破。這兩種藥物均已納入中國國家醫保藥品目錄（NRDL），大幅減輕了患者的經濟負擔。目前的研發管線中，多個具有顯著首創潛力的藥物候選者預計將為阿爾茨海默病等慢性疾病提供新的治療選擇。</p>
</div><p>Dr. Lu has actively promoted improvements in China's pharmaceutical ecosystem, including the evolution of innovative drug review pathways, NRDL inclusion mechanisms and capital market reforms. Under his guidance, Chipscreen has donated over RMB 700 million worth of medicines, helping more than 10,000 patients alleviate treatment costs. Dedicated to developing first-in-class therapies with novel targets, structures and mechanisms, he has been hailed by international media as &#34;China's pioneer of original innovative drugs.&#34;</p>
<div class="lb-trans"><p>盧博士積極推動中國製藥生態系統的改善，包括創新藥物審評路徑的演變、NRDL 納入機制和資本市場改革。在他的指導下，微芯生物已捐贈超過 7 億人民幣的藥品，幫助超過 10,000 名患者減輕治療費用。致力於開發具有新靶點、結構和機制的首創療法，他被國際媒體譽為&#34;中國原創創新藥物的先驅&#34;。</p>
</div><p>SOURCE Shenzhen Chipscreen Biosciences Co., Ltd.</p>
<div class="lb-trans"><p>來源：深圳微芯生物科技有限公司。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMjI5Jk5ld3NJdGVtSWQ9Q041NDE5NyZUcmFuc21pc3Npb25fSWQ9MjAyNTEyMjkxOTQ1UFJfTkVXU19VU1BSX19fX19DTjU0MTk3" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=CN54197&amp;Transmission_Id=202512291945PR_NEWS_USPR_____CN54197&amp;DateId=20251229"/></p>

19:45 ET
			
			
				Dr. Lu Xianping, Founder, Chairman of Chipscreen Biosciences named the Chinese mainland winner of the EY Entrepreneur Of The Year™ 2025 awards

微芯生物創始人兼董事長陸先平博士被評為安永 2025 年度企業家獎中國大陸地區獲獎者